S
Shots:
- The P-IV (PEARL) study (N=1140) evaluating fremanezumab met its 1EP and 2EPs, demonstrating long-term effectiveness over two years, significantly reducing the frequency, duration, and severity of migraine attacks in both chronic and episodic migraine pts
- The study met 1EP of ≥50% reduction in MMD within the first 6mos. of treatment. Injection adherence remained high throughout the study (~90%), and over 75% of pts completed the full two-year study duration with a consistent safety and tolerability profile
- The 2EPs include changes in MMD from baseline over 24mos., as well as treatment adherence (dosing within ±5 days of the prescribed interval) and long‑term persistence with the therapy
Ref: Globenewswire| Image: Teva | Press Release
Related News:- Dizal Reports Enrollment Completion in P-III (WU-KONG28) Trial of Sunvozertinib for EGFRm NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
